GlassScriptPhysician profile
Tyler M Conway
NPI 1104269000
$7,060.67
in general payments reported to CMS, 2019-2025
29 companies · $884 in 2025
The $884 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $492 · 2021: $725 · 2022: $1,759 · 2023: $1,532 · 2024: $893 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,110 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,109.72 |
| Education | $199.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,494.08 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,060.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $594.07 | 2019-2025 | Ilumya |
| Amgen INC. | $488.41 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $424.97 | 2019-2024 | Dupixent |
| Genzyme Corporation | $323.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $213.73 | 2019-2025 | |
| Pfizer INC. | $209.77 | 2019-2024 | |
| Galderma Laboratories, L.P. | $176.87 | 2019-2023 | Oracea, Epsolay, Aklief |
| Lilly USA, LLC | $157.48 | 2019-2023 | Taltz |
| Incyte Corporation | $131.61 | 2022-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $125.00 | 2021 | |
| Dermavant Sciences, INC. | $103.19 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $95.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $86.32 | 2019-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.74 | 2024-2025 | Spevigo |
| Celgene Corporation | $42.97 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.57 | 2019-2020 | |
| Ucb, INC. | $23.86 | 2020 | |
| Krystal Biotech INC | $23.85 | 2024 | Vyjuvek |
| Biofrontera INC. | $22.18 | 2022 | |
| Promius Pharma LLC | $17.73 | 2019 | |
| Strata Skin Sciences, INC. | $17.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2024 | Sotyktu |
| Organogenesis INC. | $14.89 | 2023 | Puraply |
| Epi Health, LLC | $11.43 | 2021 | |
| Merck Sharp & Dohme LLC | $10.99 | 2019 | |
| Organon LLC | $8.71 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Conway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.